CTLA4 and cancer: Not unexpectedly, a significant positive correlation was found between the reporting odds ratio (ROR) of reporting an irAE during anti-CTLA-4, anti-PD-1, and anti-CTLA-4/anti-PD-1 immune combination therapies and the corresponding TMB in 7677 patients across 19 cancer types [46].